Key Takeaways

An experimental drug can help many with a rare autoimmune bleeding condition

More than half of people with immune thrombocytopenia wound up with healthy platelet levels after treatment with ianalumab

The drug’s benefits lasted up to a year

FRIDAY, Dec. 12, 2025 (HealthDay News) — More than half of people with a rare life-threatening bleeding condition received lasting relief from an experimental antibody treatment, clinical trial results show.

Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without serious bleeding episodes for at least a year, according to results published Dec. 9 in The New England Journal of Medicine .

The drug achieved that after four monthly doses, researchers reported.

“This s

See Full Page